Study of IMC-P115C in Advanced PRAME-Positive Cancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorImmunocore Ltd
About this trial
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.
Eligibility criteria
Qualifiers
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
HLA-A*02:01-positive
Meeting PRAME-positive tumor testing requirements
Metastatic or unresectable solid tumors
Disqualifiers
Symptomatic or untreated central nervous system metastasis
Bowel obstruction, perforation, or fistula formation within 3 months prior to the planned first dose of study treatment
Ongoing ascites or effusion requiring recent drainages
Significant ongoing toxicity from prior anticancer treatment
Trial design
Treatments tested in this trial
- IMC-P115C
Treatment groups
140 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov